PT  - JOURNAL ARTICLE
AU  - Liu, Haiyang
AU  - Moran, Robert A.
AU  - Doughty, Emma L.
AU  - Hua, Xiaoting
AU  - Snaith, Ann E.
AU  - Zhang, Linghong
AU  - Chen, Xiangping
AU  - Guo, Feng
AU  - van Schaik, Willem
AU  - McNally, Alan
AU  - Yu, Yunsong
TI  - Changes to an intensive care unit <em>Acinetobacter baumannii</em> population following COVID-19 disruptions and targeted infection prevention interventions
AID  - 10.1101/2024.02.02.24302174
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.02.02.24302174
4099  - http://medrxiv.org/content/early/2024/02/04/2024.02.02.24302174.short
4100  - http://medrxiv.org/content/early/2024/02/04/2024.02.02.24302174.full
AB  - Carbapenem-resistant Acinetobacter baumannii (CRAB) is a persistent nosocomial pathogen that poses a significant threat to global public health. A three-month cross-sectional observational study was conducted in a 28-bed ICU in Hangzhou, China. The same ICU was sampled for the same duration and with a similar methodology in 2019, 20 months prior to the outset of this study. Following COVID-19-associated delays, a series of IPC measures targeting patients, staff and the ICU environment were implemented for 8 months prior to and throughout this study. A total of 5,341 samples were collected from the ICU environment (n = 4450) and patients (n = 891). A. baumannii isolates were obtained from 9·5% of these samples (n = 505). Most A. baumannii isolated in this ICU were CRAB (419/518; 80·9%). Fewer CRAB were isolated here (407 from 363 sampling occasions) than in 2019 (502 from 336 sampling occasions). However, MIC50/MIC90 values for imipenem increased from 32/64 mg/L in the 2019 study to 64/128 mg/L here. This was accompanied by the proportion of global clone 2 (GC2) isolates falling from 99·5% in 2019 to 50·8% (213/419) in 2021. The phylogenetic diversity of GC2 increased, apparently driven by regular introductions of distinct clusters in association with patients. The remaining CRAB (40·2%; 206/419) were a highly clonal population of ST164, which appears to have persisted in the ICU since an introduction in mid-2020. We found clusters of GC2 and ST164 isolates with identical core genomes in different room or bed unit environments, and in multiple patients, indicative of transmission in the ICU.Changes to IPC procedures in this ICU were associated with a reduction in the total prevalence of CRAB, and in the number of CRAB isolated from clinical specimens. At the phenotypic level, the CRAB population exhibited increased resistance to carbapenems, and this may be the result of increased antibiotic prescribing over the COVID-19 period. The increased diversity of this CRAB population appears to have been the result of repeated introductions to the ICU with patients, which have continued despite interventions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was undertaken as part of the DETECTIVE research project funded by the Medical Research Council (MR/S013660/1), and the National Natural Science Foundation of China (U22A20338, 32270183, 81861138054, 32011530116). W.v.S was also supported by a Wolfson Research Merit Award (WM160092). AM is also supported by the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (NIHR203326).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval and informed consent were obtained by the Sir Run Run Shaw Hospital (SRRSH) Zhejiang University local ethics committee (approval number 20190802-1). This work was part of a study registered as a clinical trial with ClinicalTrials.gov (NCT04310722).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll sequence data produced in this study are available online via NCBI under accession number PRJNA1034534